KR20210047323A - 시력 개선을 위한 알파-2-아드레날린성 수용체 효능제의 용도 - Google Patents

시력 개선을 위한 알파-2-아드레날린성 수용체 효능제의 용도 Download PDF

Info

Publication number
KR20210047323A
KR20210047323A KR1020217008132A KR20217008132A KR20210047323A KR 20210047323 A KR20210047323 A KR 20210047323A KR 1020217008132 A KR1020217008132 A KR 1020217008132A KR 20217008132 A KR20217008132 A KR 20217008132A KR 20210047323 A KR20210047323 A KR 20210047323A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
formula
improvement
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217008132A
Other languages
English (en)
Korean (ko)
Inventor
모하메드 디바스
다니엘 더블유. 길
웨인 첸
미구엘 알칸타라
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20210047323A publication Critical patent/KR20210047323A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217008132A 2018-08-21 2019-08-20 시력 개선을 위한 알파-2-아드레날린성 수용체 효능제의 용도 Withdrawn KR20210047323A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21
US62/720,671 2018-08-21
PCT/US2019/047305 WO2020041340A1 (en) 2018-08-21 2019-08-20 The use of alpha-2-adrenergic receptor agonists for improving vision

Publications (1)

Publication Number Publication Date
KR20210047323A true KR20210047323A (ko) 2021-04-29

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008132A Withdrawn KR20210047323A (ko) 2018-08-21 2019-08-20 시력 개선을 위한 알파-2-아드레날린성 수용체 효능제의 용도

Country Status (17)

Country Link
US (4) US20210205273A1 (https=)
EP (1) EP3840750A1 (https=)
JP (1) JP2021534217A (https=)
KR (1) KR20210047323A (https=)
CN (1) CN112823003A (https=)
AR (1) AR115991A1 (https=)
AU (1) AU2019325486A1 (https=)
BR (1) BR112021003295A2 (https=)
CA (1) CA3110318A1 (https=)
CL (1) CL2021000440A1 (https=)
CO (1) CO2021003460A2 (https=)
IL (1) IL280990A (https=)
MX (1) MX2021002112A (https=)
PH (1) PH12021550372A1 (https=)
SG (1) SG11202101730SA (https=)
TW (1) TW202021584A (https=)
WO (1) WO2020041340A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514732A (ja) * 2020-02-20 2023-04-07 アラーガン、インコーポレイテッド アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用
US12023276B2 (en) 2021-02-24 2024-07-02 Ocular Therapeutix, Inc. Intracanalicular depot inserter device
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
WO2012149381A1 (en) * 2011-04-28 2012-11-01 Alpha Synergy Development, Inc. Compositions and methods for improving night vision
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
JP2016515583A (ja) 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN103338483B (zh) * 2013-07-24 2016-08-10 成都西加云杉科技有限公司 数据分流方法、数据分流设备及异构网络
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Also Published As

Publication number Publication date
WO2020041340A1 (en) 2020-02-27
JP2021534217A (ja) 2021-12-09
BR112021003295A2 (pt) 2021-05-18
AU2019325486A1 (en) 2021-03-25
CO2021003460A2 (es) 2021-04-08
AR115991A1 (es) 2021-03-17
EP3840750A1 (en) 2021-06-30
MX2021002112A (es) 2021-07-16
US20220288031A1 (en) 2022-09-15
SG11202101730SA (en) 2021-03-30
PH12021550372A1 (en) 2021-11-29
IL280990A (en) 2021-04-29
US20240358682A1 (en) 2024-10-31
US20210205273A1 (en) 2021-07-08
CN112823003A (zh) 2021-05-18
CA3110318A1 (en) 2020-02-27
CL2021000440A1 (es) 2021-09-20
TW202021584A (zh) 2020-06-16
US20220160623A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US20240358682A1 (en) Use of alpha-2-adrenergic receptor agonists for improving vision
Fukuyama et al. Relationship between apparent accommodation and corneal multifocality in pseudophakic eyes
RU2657514C2 (ru) Офтальмологический состав и способ для облегчения пресбиопии
KR102472774B1 (ko) 안과용 약학 조성물 및 이와 관련된 용도
AU2016396661B2 (en) Cross-linking agents and associated methods
US20240390330A1 (en) Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes
JP2020509085A (ja) アトロピンを含む、近視の発症を予防するまたは遅らせるための組成物および方法
US11077053B2 (en) Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US20240335425A1 (en) Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision
Goss et al. Optometric clinical practice guideline care of the patient with myopia
Gündüz et al. Lenticular astigmatism in tilted disc syndrome
HK40053072A (en) The use of alpha-2-adrenergic receptor agonists for improving vision
Ramchandran et al. Vision impairment and its management in older adults
HK40120042A (zh) 包含阿托品的用於防止或延迟近视发作的组合物和方法
HK40107891A (en) Cross-linking agents and associated methods

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210318

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250227

Patent event code: PE09021S01D

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250310

WITB Written withdrawal of application